A longitudinal cohort study of the relationship between Thimerosal-containing hepatitis B vaccination and specific delays in development in the United States: Assessment of attributable risk and lifetime care costs

Journal of Epidemiology and Global Health

Volumn 6, Issue 2, 2016, Pages 105-118

  Geier, David A ^a   Kern, Janet K ^a   Hooker, Brian S ^b   King, Paul G ^c   Sykes, Lisa K ^c   Geier, Mark R ^a  

^a Institute of Chronic Illnesses Inc   (United States)

^b Simpson University   (United States)

^c Department of Research   (United States)

Author keywords

Ethylmercury; Merthiolate; Thimerosal; Thiomersal; Vaccine

Indexed keywords

HEPATITIS B VACCINE; ORGANOMERCURY COMPOUND; THIOMERSAL; ANTIVIRUS AGENT; MERCURY;

ARTICLE; ATTRIBUTABLE RISK; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; FEMALE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; INFANT; LEARNING DISORDER; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES; VACCINATION; CHILD DEVELOPMENT; DRUG EFFECTS; ECONOMICS; HEPATITIS B; NEWBORN; PRESCHOOL CHILD; RISK FACTOR;

ANTIVIRAL AGENTS; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; MALE; MERCURY; RISK FACTORS; THIMEROSAL; UNITED STATES;

EID: 84945565488     PISSN: 22106006     EISSN: 22106014     Source Type: Journal    
DOI: 10.1016/j.jegh.2015.06.002     Document Type: Article

References (46)

1. Geier D.A., Sykes L.K., Geier M.R. A review of Thimerosal (Merthiolate) and its ethylmercury breakdown product: specific historical considerations regarding safety and effectiveness. J Toxicol Environ Health B Crit Rev 2007, 10:575-596.
2. Tan M., Parkin J.E. Route of decomposition of thiomersal (thimerosal). Int J Pharm 2000, 208:23-34.
3. Trumpler S., Meermann B., Nowak S., Buscher W., Karst U., Sperling M. In vitro study of thimerosal reactions in human whole blood and plasma surrogate samples. J Trace Elem Med Biol 2014, 28:125-130.
4. Kern J.K., Haley B.E., Geier D.A., Sykes L.K., King P.G., Geier M.R. Thimerosal exposure and the role of sulfation chemistry and thiol availability in autism. Int J Environ Res Public Health 2013, 10:3771-3800.
5. Wehe C.A., Pieper I., Holtkamp M., Thyssen G.M., Sperling M., Schwerdtle T., et al. On-line species isotope dilution analysis in the picomolar range reveals the time- and species-depending mercury uptake in human astrocytes. Anal Bioanal Chem 2014, 406:1909-1916.
6. Zimmermann L.T., Santos D.B., Naime A.A., Leal R.B., Dorea J.G., Barbosa F., et al. Comparative study of methyl- and ethylmercury-induced toxicity in C6 glioma cells and the potential role of LAT-1 in mediating mercurial-thiol complexes uptake. Neurotoxicology 2013, 38:1-8.
7. Geier M.R., Geier D.A. Neurodevelopmental disorders after Thimerosal-containing vaccines: a brief communication. Exp Biol Med (Maywood) 2003, 228:660-664.
8. Geier D.A., Kern J.K., King P.G., Sykes L.K., Geier M.R. The risk of neurodevelopmental disorders following a Thimerosal-preserved DTaP formulation in comparison to its Thimerosal-reduced formulation in the Vaccine Adverse Event Reporting System (VAERS). J Biochem Pharm Res 2014, 2:64-73.
9. Geier D.A., Kern J.K., Hooker B.S., King P.G., Sykes L.K., Geier M.R. Thimerosal-containing hepatitis B vaccination and the risk for diagnosed specific delays in development in the United States: a case control-study in the Vaccine Safety Datalink. N Am J Med Sci 2014, 6:519-531.
10. Young H.A., Geier D.A., Geier M.R. Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink. J Neurol Sci 2008, 271:110-118.
11. Gallagher C., Goodman M. Hepatitis B triple series vaccine and developmental disability in US children aged 1-9 years. Toxicol Environ Chem 2008, 90:997-1008.
12. Chen R.T., DeStefano F., Davis R.L., Jackson L.A., Thompson R.S., Mullooly J.P., et al. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ 2000, 78:186-194.
13. Chen R.T., Glasser J.W., Rhodes P.H., Davis R.L., Barlow W.E., Thompson R.S., et al. The Vaccine Safety Datalink Team. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics 1997, 99:765-773.
14. Wassilak S.G., Glasser J.W., Chen R.T., Hadler S.C. The Vaccine Safety Datalink Investigators. Utility of large-linked databases in vaccine safety, particularly in distinguishing independent and synergistic effects. Ann N Y Acad Sci 1995, 754:377-382.
15. American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Environmental Health. Thimerosal in vaccines-an interim report to clinicians. Pediatrics 1999;104(3 Pt 1):570-4.
16. Ellenberg S.S., Braun M.M. Monitoring the safety of vaccines: assessing the risks. Drug Saf 2002, 25:145-152.
17. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40(RR-13):1-25.
18. Ball L.K., Ball R., Pratt R.D. An assessment of thimerosal use in childhood vaccines. Pediatrics 2001, 107:1147-1154.
19. Geier D.A., Geier M.R. An assessment of downward trends in neurodevelopmental disorders in the United States following removal of Thimerosal from childhood vaccines. Med Sci Monit 2006, 12:CR231-CR239.
20. Centers for Disease Control and Prevention. Table 1-1. Live Births, Birth Rates, and Fertility Rates, by Race: United States, 1909-2003. Available at: . Accessed 04/27/2015. http://www.cdc.gov/nchs/data/statab/natfinal2003.annvol1_01.pdf.
21. Aspray T.J., Francis R.M., Tyrer S.P., Quilliam S.J. Patients with learning disability in the community have special medical needs that should be planned for. BMJ 1999, 318:476-477.
22. The Roeher Institute. Learning Disabilities in Canada: Economic Costs to Individuals, Families, and Society. Final Report and Executive Summary. Revised January, 2002. Available at: . Accessed 04/27/2015. http://justinevesfoundation.com/wp-content/uploads/2014/01/Research_EconomicCosts-LD.pdf.
23. Buescher A.V., Cidav Z., Knapp M., Mandell D.S. Costs of autism spectrum disorders in the United Kingdom and the United States. JAMA Pediatr 2014, 168:721-728.
24. Pelham W.E., Foster M.E., Robb J.A. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol 2007, 32:711-727.
25. Dorea J.G. Low-dose mercury exposure in early life: relevance of Thimerosal to fetuses, newborns, and infants. Curr Med Chem 2013, 20:4060-4069.
26. Burbacher T.M., Shen D.D., Liberato N., Grant K.S., Cernichiari E., Clarkson T. Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing Thimerosal. Environ Health Perspect 2005, 113:1015-1021.
27. Carneiro M.F., Oliveira Souza J.M., Grotto D., Batista B.L., de Oliveira Souza V.C., Barbosa F. A systematic study of the disposition and metabolism of mercury species in mice after exposure to low levels of thimerosal (ethylmercury). Environ Res 2014, 134:218-227.
28. Rodrigues J.L., Serpeloni J.M., Batista B.L., Souza S.S., Barbosa F. Identification and distribution of mercury species in rat tissues following administration of thimerosal or methylmercury. Arch Toxicol 2010, 84:891-896.
29. Kern J.K., Geier D.A., Audhya T., King P.G., Sykes L.K., Geier M.R. Evidence of parallels between mercury intoxication and the brain pathology of autism. Acta Neurobiol Exp (Wars) 2012, 72:113-153.
30. Hornig M., Chian D., Lipkin W.I. Neurotoxic effects of postnatal Thimerosal are mouse strain dependent. Mol Psychiatr 2004, 9:833-845.
31. Olczak M., Duszczyk M., Mierzejewski P., Meyza K., Majewska M.D. Persistent behavioral impairments and alterations of brain dopamine system after early postnatal administration of Thimerosal in rats. Behav Brain Res 2011, 223:107-118.
32. Chen Y.N., Wang J., Zhang J., Li S.J., Hel L., Shao D.D., et al. Effect of Thimerosal on the neurodevelopment of premature rats. World J Pediatr 2013, 9:356-360.
33. Sulkowski Z.L., Chen T., Midha S., Zavacki A.M., Sajdel-Sulkowska E.M. Maternal Thimerosal exposure results in aberrant cerebellar oxidative stress, thyroid hormone metabolism, and motor behavior in rat pups; sex- and strain-dependent effects. Cerebellum 2012, 11:575-586.
34. Laurente J., Remuzgo F., Avalos B., Chiquinta J., Ponce B., Avendano R., et al. Neurotoxic effects of Thimerosal at vaccines doses on the encephalon and development in 7 days-old hamsters. An Fac Med Lima 2007, 68:222-237.
35. Hewitson L., Houser L.A., Stott C., Sackett G., Tomko J.L., Atwood D., et al. Delayed acquisition of neonatal reflexes in newborn primates receiving a Thimerosal-containing hepatitis B vaccine: influence of gestational age and birth weight. J Toxicol Environ Health A 2010, 73:1298-1313.
36. Hagmann P., Cammoun L., Gigandet X., Meuli R., Honey C.J., Wedeen V.J., et al. Mapping the structural core of human cerebral cortex. PLoS Biol 2008, 6:e159.
37. Fujioka T., Mourad N., Trainor L.J. Development of auditory-specific brain rhythm in infants. Eur J Neurosci 2011, 33:521-529.
38. Smith J.B., Alloway K.D. Functional specificity of claustrum connections in the rat: interhemispheric communication between specific parts of motor cortex. J Neurosci 2010, 30:16832-16844.
39. Wandell B.A., Yeatman J.D. Biological developing of reading circuits. Curr Opin Neurobiol 2013, 23:261-268.
40. Yeatman J.D., Dougherty R.F., Ben-Shachar M., Wandell B.A. Developing of white matter and reading skills. Proc Natl Acad Sci U S A 2012, 109:E3045-E3053.
41. Jeong J.W., Sundaram S.K., Kumar A., Chugani D.C., Chugani H.T. Aberrant diffusion and geometric properties in the left arcuate fasciculus of developmentally delayed children: a diffusion tensor imaging study. AJNR Am J Neuroradiol 2011, 32:323-330.
42. Pallocca G., Fabbri M., Sacco M.G., Gribaldo L., Pamies D., Laurenza I., et al. MiRNA expression profiling in a human stem cell-based model as a tool for developmental neurotoxicity testing. Cell Biol Toxicol 2013, 29:239-257.
43. Hewitson L., Lopresti B.J., Stott C., Mason N.S., Tomko J. Influence of pediatric vaccines on amygdala growth and opioid ligand binding in rhesus macaque infants: a pilot study. Acta Neurobiol Exp (Wars). 2010, 70:147-164.
44. Andrews N., Miller E., Grant A., Stowe J., Osborne V., Taylor B. Thimerosal exposure in infants and developmental disorders: retrospective cohort study in the United Kingdom does not support a causal association. Pediatrics 2004, 114:584-591.
45. Verstraeten T., Davis R.L., DeStefano F., Lieu T.A., Rhodes P.H., Black S.B., et al. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics 2003, 112:1039-1048.
46. Hooker B., Kern J., Geier D., Haley B., Sykes L., King P., et al. Methodological issues and evidence of malfeasance in research purporting to show Thimerosal in vaccines is safe. Biomed Res Int 2014, 2014:247218.